We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$615M
Cap. Flow %
-7.41%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
26
DELISTED
Immunomedics Inc
IMMU
$90.2M 1.09%
4,328,573
-616,000
-12% -$14.6M
BOLD
27
DELISTED
Audentes Therapeutics, Inc
BOLD
$86.3M 1.04%
2,180,000
-435,000
-17% -$16.2M
NVRO
28
DELISTED
NEVRO CORP.
NVRO
$77.4M 0.93%
1,357,691
+97,600
+8% +$6.1M
A icon
29
Agilent Technologies
A
$39.9B
$76.5M 0.92%
1,085,100
-800,000
-42% -$52.9M
PRNB
30
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$76.1M 0.92%
+2,605,713
New +$73.5M
DCPH
31
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$75.6M 0.91%
1,953,500
-52,200
-3% -$1.93M
AERI
32
DELISTED
Aerie Pharmaceuticals
AERI
$75.1M 0.9%
1,219,830
-664,270
-35% -$42.7M
ACET icon
33
Adicet Bio
ACET
$76.7M
$73.1M 0.88%
43,128
– –
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$73.1M 0.88%
4,806,900
-94,000
-2% -$1.44M
MOH icon
35
Molina Healthcare
MOH
$10.6B
$72.7M 0.88%
+488,781
New +$62.4M
XRAY icon
36
Dentsply Sirona
XRAY
$2.79B
$71.3M 0.86%
1,889,200
-504,300
-21% -$21M
MD icon
37
Pediatrix Medical
MD
$2.18B
$68.6M 0.83%
1,469,300
+606,700
+70% +$27.9M
BLUE
38
DELISTED
bluebird bio
BLUE
$67M 0.81%
35,450
-2,239
-6% -$4.63M
CLVS
39
DELISTED
Clovis Oncology, Inc.
CLVS
$65.6M 0.79%
2,234,570
-96,300
-4% -$3.73M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.04B
$62.4M 0.75%
5,548,326
– –
PTCT icon
41
PTC Therapeutics
PTCT
$6.21B
$59.9M 0.72%
+1,275,000
New +$52.8M
JNJ icon
42
Johnson & Johnson
JNJ
$644B
$57.2M 0.69%
414,100
-341,900
-45% -$45.4M
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
$56.4M 0.68%
330,000
-208,000
-39% -$35M
CRNX icon
44
Crinetics Pharmaceuticals
CRNX
$8.87B
$54.8M 0.66%
+1,914,282
New +$56.8M
ARGX icon
45
argenx
ARGX
$55B
$54.5M 0.66%
718,800
+119,500
+20% +$10.6M
IRWD icon
46
Ironwood Pharmaceuticals
IRWD
$612M
$54.1M 0.65%
3,497,525
– –
VRAY
47
DELISTED
ViewRay, Inc.
VRAY
$53.7M 0.65%
5,736,267
-3,722,300
-39% -$36.6M
ISRG icon
48
Intuitive Surgical
ISRG
$128B
$52.9M 0.64%
276,600
-54,900
-17% -$9.75M
CRVS icon
49
Corvus Pharmaceuticals
CRVS
$1.11B
$51.2M 0.62%
5,967,584
– –
EXEL icon
50
Exelixis
EXEL
$14B
$49.6M 0.6%
2,801,900
+1,120,700
+67% +$21.9M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.